Recent Pfizer Press Releases

  • 2/2/16 6:45 am EST

    PROVIDES 2016 FINANCIAL GUIDANCE

    • Fourth-Quarter 2015 Reported Revenues(1) of $14.0 Billion, Reflecting 14% Operational Growth Driven by 22% Operational Growth from the Innovative Products Business
    • Full-Year 2015 Reported Revenues(1) of $48.9 Billion, Reflecting 6% Operational Growth Driven by 19% Operational Growth from the Innovative Products Business
    • Fourth-Quarter 2015 Adjusted Diluted EPS(2) of $0.53 and Reported Diluted EPS(1) of $0.10; Full-Year 2015 Adjusted Diluted EPS(2) of $2.20 and Reported Diluted EPS(1) of $1.24
    • Provides 2016 Financial Guidance
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2015 and provided 2016 financial guidance. On September 3, 2015, Pfizer acquired Hospira, Inc. (Hospira). Consequently, and in accordance with Pfizer's domestic and international reporting periods(3), full-year financial results for the year ended December 31, 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospiramore...
  • 2/1/16 6:55 am EST
    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NSYE:PFE) today announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq: PTLA) to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, includingmore...
  • 1/13/16 7:04 pm EST
    SHANGHAI--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has acquired Sirio Pharma Co. Ltd.’s wholly-owned subsidiary, Treerly Health Co., Ltd., and its family of Treerly products. Treerly is one of the top healthcare brands in China’s retail channel and consists of an extensive portfolio of products uniquely designed to meet women’s nutritional healthcare needs throughout their lives. The Treerly portfolio complements Pfizer Consumer Healthcare’more...
  • 1/11/16 8:32 am EST

    Campaign Marks Brand’s Focus on Skincare for Lips

    MADISON, N.J.--(BUSINESS WIRE)--Pfizer® Consumer Healthcare, the makers of ChapStick®, America’s favorite lip balm, today announced actress Rachel Bilson as the brand’s newest spokesperson. Rachel will appear in a robust marketing campaign to elevate the importance of skincare for lips and communicate the iconic brand’s continued innovation. Rachel’s partnership with the brand will focus on the advanced skincare line featuring ChapStick® Total Hydration 100% Naturalmore...
  • 1/8/16 4:13 pm EST

    Initial Investments in Companies Focused on Conditionally Active Biologics, Immuno-Oncology, Neurodegenerative Technologies and Gene Therapy Provide Access to Pfizer Resources to Help Accelerate Research into Novel Pathways and Technologies

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced an expansion of its Research & Development (R&D) investment strategy to include early-stage companies on the leading edge of scientific innovation, providing them with both equity and access to resources for research in promising areas aligned with Pfizer’s core interests. The first four investments of the newly focused initiative include $46 million in financing to companies at early stages of themore...
  • 1/8/16 8:00 am EST
    NEW YORK & SEATTLE--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise. Under the terms of the agreement, Pfizer and Adaptive will seek to combine drug development and platform technology biomarker expertise to identify patients who may preferentially benefit frommore...
  • 1/5/16 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a joint discussion with Pfizer and Allergan management at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 10:30 a.m. Pacific Standard Time. Pfizer speakers will be Ian Read, Chairman and CEO, Mikael Dolsten, President, Worldwide Research and Development, and Albert Bourla, Group President, Vaccines, Oncology and Consumermore...
  • 1/4/16 8:00 am EST
    • Merck KGaA, Darmstadt, Germany, Pfizer and Syndax will collaborate to investigate safety, tolerability and preliminary efficacy of avelumab and entinostat in advanced ovarian cancer
    DARMSTADT, Germany & NEW YORK & WALTHAM, Mass.--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s entinostat, an investigational oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells and regulatory T-cells), in patients with heavily pre-treated,more...
  • 12/22/15 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 2, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2015 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.more...
  • 12/22/15 8:00 am EST
    • Initiation of Phase III JAVELIN Ovarian 200 trial investigating avelumab as a treatment for platinum-resistant/refractory ovarian cancer
    • Initiation of Phase III JAVELIN Bladder 100 trial investigating avelumab as a maintenance treatment, in the first-line setting, for patients with urothelial cancer
    • Merck KGaA, Darmstadt, Germany-Pfizer Alliance achieves 2015 goal of initiating six pivotal trials with JAVELIN Ovarian 200 and JAVELIN Bladder 100 trials
    DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany and Pfizer today announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer. The JAVELIN Ovarian 200 trial is the first Phase III study of a PD-L1 inhibitor investigated as a treatment for platinum-resistant/refractory ovarian cancer. The alliance alsomore...